PD L1 News and Research

RSS

Lung cancer patients treated with immune checkpoint inhibitors can be safely vaccinated against COVID-19, study says

Cancer patients have received priority status to receive COVID-19 vaccinations but there is limited data regarding the safety and efficacy of the vaccines for patients treated for lung cancer with immune checkpoint inhibitors.

22 Jun 2022

HIV coinfection significantly impacts B cell response to SARS-CoV-2

In recent research posted to the bioRxiv* preprint server, investigators confirmed that human immunodeficiency virus (HIV) co-infection alters B cell reaction in coronavirus disease 2019 (COVID-19).

17 Jun 2022

Liquid biopsy could better predict immunotherapy response in lung cancer patients than tumor biopsy

Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure.

3 Jun 2022

UCLA researchers identify a method to make tumors susceptible to immune attack

One powerful way cancer cells defend against tumor-killing immune cells is to load up their cell surface with a protein known as PD-L1. Now a team of UCLA Jonsson Comprehensive Cancer Center researchers led by Roger S. Lo, MD, PhD, has identified a method to degrade tumor cell-surface PD-L1, thereby making tumors susceptible to immune attack.

31 May 2022

Blood-based biomarker can predict the benefit of immunotherapy to lung cancer patients

A blood-based tumor biomarker can predict the benefit of immunotherapy to patients with non-small cell lung cancer, according to a study published in Nature Medicine.

20 May 2022

First patient dosed in Phase 1 clinical trial evaluating the safety of CF33-hNIS against solid tumors

Imugene Limited, a clinical stage immuno-oncology company, and City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient was dosed in a Phase 1 clinical trial evaluating the safety of novel cancer-killing virus CF33-hNIS VAXINIA when used in people with advanced solid tumors.

18 May 2022

Immunotherapy combined with chemoradiation and surgery could help treat nonmetastatic gastroesophageal cancer

Immunotherapy has transformed treatment for patients with stage 4 metastatic esophageal and gastric cancers. In patients with these malignancies, immunotherapy has been shown to prolong survival when patients' tumors exhibit a high expression of an immune-related protein called PD-L1.

16 May 2022

Immunotherapy after bladder cancer surgery helps reduce cancer recurrence

Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle and therefore posed a high risk for recurrence, according to clinical trial results presented at the American Urological Association annual meeting in May.

15 May 2022

Stem cell therapy prevents type 1 diabetes induced by anti-cancer drugs

Immune checkpoint inhibitors are widely used to treat a variety of cancers; however, one serious side effect is the onset of type 1 diabetes.

6 May 2022

Study assesses the efficacy and safety of lithium treatment in patients infected with severe SARS-CoV-2

Researchers assessed the efficacy and safety of using lithium for coronavirus disease 2019 (COVID-19) treatment.

5 May 2022

Study reveals a complexity to how the body "regulates the regulators" of the immune system

Checkpoint inhibitors have become important tools in the cancer-fighting arsenal. By blocking proteins that normally restrain the immune response, these drugs can help the immune system destroy cancer cells.

20 Apr 2022

Recent advances in non-viral nano-vector delivery of CRISPR/Cas9 genome editing payloads

Researchers reviewed non-viral nano-vectors used for delivering the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-mediated genome editing system.

14 Apr 2022

New bioinformatics platform predicts optimal treatment combinations for cancer patients

Researchers at The University of Texas MD Anderson Cancer Center have developed a new bioinformatics platform that predicts optimal treatment combinations for a given group of patients based on co-occurring tumor alterations.

12 Apr 2022

Study finds better immunotherapy response in lung cancer patients with genetic variant linked to autoimmune disease

A variant of the CTLA-4 gene associated with autoimmune disease was found to be more frequent in non-small cell lung cancer (NSCLC) patients who experienced an exceptionally high response to anti-PD-1 immunotherapy and higher immune-related side effects than in a comparable cohort of lung cancer patients and healthy individuals, according to data presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

NSCLC patients treated with KRAS G12C inhibitor sotorasib may receive long-term clinical benefit

Patients with non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitor sotorasib (Lumakras) had a two-year overall survival rate of 32.5 percent, according to data from the CodeBreaK 100 clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

Combination immunotherapy reverses resistance to PD-1 inhibitors in patients with advanced melanoma

Patients with advanced melanoma whose cancer does not respond to treatment with widely used immunotherapy drugs known as PD-1 inhibitors are often switched to treatment with a second type of immunotherapy drug – a CTLA-4 inhibitor such as the drug ipilimumab.

8 Apr 2022

City of Hope's late-breaking clinical trial data to be presented at AACR

Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, will present late-breaking and clinical trial findings at this year's American Association for Cancer Research Annual Meeting, which begins today.

8 Apr 2022

Natural compound found in cardamom shows promise for treating triple-negative breast cancer

Cardamonin - a natural compound found in the spice cardamom and other plants - could have therapeutic potential for triple-negative breast cancer, according to a new study using human cancer cells.

3 Apr 2022

Biological timeline of COVID-19 immune recovery described in new research

In a recent study published on the bioRxiv* preprint server, a group of researchers from the University of California, San Francisco, looked at intra-patient immunological changes over time to see if there were any changes in immune responses associated with successful COVID-19 resolution.

21 Mar 2022

Trial shows safety and immunogenicity of immunotherapy with chemoradiation in cervical cancer patients

A Phase I/Ib trial conducted by the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group NRG Oncology, NRG-GY017, concluded that the addition of the immunotherapy drug atezolizumab prior to and concurrently given with chemoradiation (CRT) treatment was safe for women with node-positive, locally advanced cervical cancer.

19 Mar 2022